CNS Drugs

, Volume 12, Issue 3, pp 171–177 | Cite as

Discontinuation Syndromes with Selective Serotonin Reuptake Inhibitors

Are There Clinically Relevant Differences?
  • James S. Olver
  • Graham D. Burrows
  • Trevor R. Norman
Leading Article

Abstract

Selective serotonin (5-hydroxytryptamine; 5-HT) reuptake inhibitors (SSRIs), like the tricyclic antidepressants and monoamine oxidase inhibitors, are associated with a well recognised syndrome following discontinuation or dose reduction. There appear to be differences in the incidence of discontinuation syndromes within the class of SSRIs. Published case reports and adverse drug reaction reports both suggest the highest incidence of the syndrome with paroxetine and the lowest incidence with fluoxetine, while other SSRIs are associated with an intermediate incidence. Open label comparison and placebo-controlled double-blind studies support this contention.

There is little evidence to separate discontinuation syndromes with different SSRIs on the basis of clinical presentation. Although the pathogenesis of SSRI discontinuation syndromes is unknown, both pharmacodynamic and pharmacokinetic factors may explain differences in incidence with individual SSRIs.

SSRI discontinuation syndromes are usually mild and transient, and prevention is the most effective management strategy.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Kuhn R. On the treatment of depressive states with an iminodibenzyl derivative (G 22355). Nederlansch Tijdschrift Voor Geneeskunde 1957; 87: 1135Google Scholar
  2. 2.
    Lader M. Benzodiazepine withdrawal states. In: Trimble MR, editor. Benzodiazepines divided. New York (NY): John Wiley &Sons, 1983: 17–31Google Scholar
  3. 3.
    Haddad P. The SSRI discontinuation syndrome. J Psychopharmacol 1998; 12(3); 305–13PubMedCrossRefGoogle Scholar
  4. 4.
    Gillespie C, Wildgust HJ, Haddad P, et al. SSRIs and withdrawal syndrome. Presented at the X World Congress of Psychiatry, 1996 Aug; Madrid, 23–28Google Scholar
  5. 5.
    Haddad P. Newer antidepressants and the discontinuation syndrome. J Clin Psychol 1997; 58 Suppl. 7: 17–22Google Scholar
  6. 6.
    Adverse Drug Reactions Advisory Committee. Aust Adv Drug React Bull 1996; 15: 3Google Scholar
  7. 7.
    Price JS, Waller PC, Wood SM, et al. A comparison of the post-marketing safety of four selective serotonin re-uptake inhibitors including the investigation of symptoms occurring on withdrawal. Br J Clin Pharmacol 1996; 42: 757–63PubMedCrossRefGoogle Scholar
  8. 8.
    Stahl MMS, Lindquist M, Pettersson M, et al. Withdrawal reactions with selective serotonin re-uptake inhibitors as reported to the WHO system. Eur J Clin Pharmacol 1997; 53: 163–9PubMedCrossRefGoogle Scholar
  9. 9.
    Coupland NJ, Bell CJ, Potokar JP. Serotonin reuptake inhibitor withdrawal. J Clin Psychopharmacol 1996; 16: 356–62PubMedCrossRefGoogle Scholar
  10. 10.
    Rosenbaum JF, Fava M, Hoog SL, et al. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomised clinical trial. Biol Psychol 1998; 44: 77–87CrossRefGoogle Scholar
  11. 11.
    Hamilton M. A rating scale for depression. J Neurol Neurosurg Psych 1960; 23: 56–62CrossRefGoogle Scholar
  12. 12.
    Zajecka J, Fawcett J, Amsterdam J, et al. Safety of abrupt discontinuation of fluoxetine: a randomised, placebo controlled study. J Clin Psychopharmacol 1998; 18: 193–7PubMedCrossRefGoogle Scholar
  13. 13.
    Oehrberg S, Christiansen PE, Behnke K, et al. Paroxetine in the treatment of panic disorder: a randomised, double-blind, placebo-controlled study. Br J Psychol 1995; 167: 374–9CrossRefGoogle Scholar
  14. 14.
    Dilsaver SC. Withdrawal phenomena associated with antidepressant and anti psychotic agents. Drug Saf 1994; 10(2): 103–14PubMedCrossRefGoogle Scholar
  15. 15.
    Lucot JB, Crampton GH. 8-OH-DPAT suppreses vomiting in the cat elicited by motion, cisplatin or xylazine. Pharmacol Biochem Behav 1989; 33(3): 627–31PubMedCrossRefGoogle Scholar
  16. 16.
    Richelson E. The pharmacology of antidepressants at the synapse: focus on the newer compounds. J Clin Psych 1994; 55 Suppl. A: 34–9Google Scholar
  17. 17.
    Preskorn SH. Clinical pharmacology of selective serotonin reuptake inhibitors. 1st ed. Caddo (OK): Professional Communications Inc., 1996Google Scholar

Copyright information

© Adis International Limited 1999

Authors and Affiliations

  • James S. Olver
    • 1
  • Graham D. Burrows
    • 1
  • Trevor R. Norman
    • 1
  1. 1.Department of Psychiatry, Austin & Repatriation Medical CentreThe University of MelbourneHeidelberg, MelbourneAustralia

Personalised recommendations